Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary. Acifran (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid is a small-molecule agonist targeting the hydroxycarboxylic acid receptors HM74A/GPR109A and GPR109B, with a molecular weight of 218.21 and formula C12H10O4 (APExBIO, product page). Recent cryo-EM studies confirm Acifran’s high-affinity, selective binding at both HCAR2 and HCAR3 (GPR109A/B) (Ye et al., 2025, DOI). Its use in research enables precise dissection of GPCR-mediated lipid signaling pathways and lipid metabolism regulation in cell models. Acifran’s solubility profile is less than 21.82 mg/ml in DMSO or ethanol, and it requires -20°C storage for optimal stability (APExBIO). The compound is not intended for diagnostic or therapeutic use but is positioned as a high-fidelity tool for metabolic disease modeling.

Biological Rationale

Lipid metabolism is tightly controlled by G-protein coupled receptors (GPCRs), including HM74A (GPR109A, HCAR2) and GPR109B (HCAR3), which act as metabolite-sensing regulators in adipose tissue and immune cells. Dysregulation of these pathways is implicated in disorders such as dyslipidemia, atherosclerosis, and other cardiovascular diseases (Ye et al., 2025). Selective agonists—such as Acifran—enable researchers to probe the molecular mechanisms and therapeutic potential of modulating these GPCRs for lipid-lowering interventions. Acifran’s validated target specificity supports its deployment in studies elucidating lipid homeostasis, cAMP signaling, and metabolic disorder pathophysiology (Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo...). This article extends prior coverage by providing a granular, citation-backed summary of molecular action and research usage parameters.

Mechanism of Action of Acifran

Acifran functions as a selective agonist for both HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) GPCRs. Upon binding, it induces conformational changes in the receptor, stabilizing the active Gi-coupled state as observed in cryo-electron microscopy (cryo-EM) structures at 2.72–3.18 Å resolution (Ye et al., 2025). This interaction initiates Gi protein signaling, reducing intracellular cAMP levels and modulating downstream lipid metabolism and anti-inflammatory pathways. Acifran’s ligand-receptor binding is dictated by occupation of orthosteric pocket regions (R1 and R2) and stabilized by π–π interactions with key residues (F1073.32 in HCAR3, L1073.32 in HCAR2) (Acifran: HM74A/GPR109A Agonist for Advanced Lipid Metabol...). Compared to nonselective ligands, Acifran exhibits high selectivity and defined functional outcomes without triggering HCAR2-specific adverse effects (e.g., cutaneous flushing).

Evidence & Benchmarks

• Acifran binds HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) with high specificity, as demonstrated by 2.72–3.18 Å cryo-EM structures (Ye et al., 2025, DOI).
• Structural studies confirm Acifran’s occupation of orthosteric binding sites and interactions with key receptor residues, supporting selectivity (Ye et al., 2025, DOI).
• Functional cAMP assays in HEK-293 cells demonstrate that Acifran induces Gi-mediated signaling and suppresses cAMP production upon receptor activation (Ye et al., 2025, DOI).
• Acifran exhibits < 21.82 mg/ml solubility in both DMSO and ethanol at room temperature (APExBIO, product page).
• For reproducible receptor-ligand studies, Acifran must be stored at -20°C, and solutions are stable only short-term (APExBIO, product page).
• Recent guidance demonstrates Acifran’s reproducibility and reliability in cell-based GPCR signaling workflows (Acifran (SKU B6848): Scenario-Driven Solutions for Reliab...).

Applications, Limits & Misconceptions

Acifran is used exclusively for scientific research to interrogate lipid metabolism regulation and GPCR signaling. Its key applications include:

• Characterization of receptor-ligand interactions for HM74A/GPR109A and GPR109B in cell models.
• Dissection of cAMP-mediated lipid signaling pathways.
• Benchmarking of hypolipidemic agent efficacy in metabolic disorder research.
• Modeling dyslipidemia, hyperlipidemia, and cardiovascular disease mechanisms (Unraveling Lipid Signaling Pathways: Acifran as a Transla...; this article clarifies mechanistic boundaries and experimental parameters beyond prior translational overviews).

Common Pitfalls or Misconceptions

• Acifran is not approved or intended for diagnostic or therapeutic use in humans or animals (APExBIO).
• Solubility limits (< 21.82 mg/ml in DMSO/ethanol) require careful solution preparation; exceeding concentrations may lead to precipitation and assay artifacts (APExBIO).
• Long-term solution storage leads to degradation; only freshly prepared aliquots at -20°C maintain bioactivity.
• While highly selective for HM74A/GPR109A and GPR109B, Acifran may not recapitulate all in vivo lipid metabolic processes due to cell model limitations (Acifran (SKU B6848): Reliable Agonist for Lipid Metabolis...; this piece details best practices to avoid experimental drift).
• Not all GPCRs or metabolite-sensing pathways are activated by Acifran; its effects are limited to its validated receptor targets.

Workflow Integration & Parameters

Acifran (SKU B6848) is supplied by APExBIO as an off-white solid for research use only (product page). To ensure experimental reproducibility:

• Reconstitute Acifran in DMSO or ethanol to a maximum of 21.82 mg/ml; filter-sterilize if necessary.
• Aliquot and store stock solutions at -20°C; avoid repeated freeze-thaw cycles.
• Prepare working solutions fresh before use; limit usage to short-term applications (<24 hours at 4°C).
• Perform receptor-ligand or GPCR signaling assays using validated cell lines (e.g., HEK-293) and controlled buffer conditions.
• Include appropriate positive and negative controls to benchmark Acifran’s specificity and functional readouts (Acifran (SKU B6848): Scenario-Driven Solutions for Reliab...; this guide extends workflow optimization details).

Conclusion & Outlook

Acifran is a well-characterized, selective agonist for HM74A/GPR109A and GPR109B, providing a robust platform for lipid metabolism and GPCR signaling research. Its structural validation, reproducibility, and defined solubility and storage parameters position it as a gold-standard research tool for metabolic disorder modeling. As new structural and functional data emerge, Acifran will remain integral to dissecting lipid regulation pathways and benchmarking hypolipidemic agent efficacy. For full product details and handling guidelines, visit the official Acifran product page (APExBIO).